These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 32930144)
1. Successful treatment of nonsmall cell lung cancer patients with leptomeningeal metastases using whole brain radiotherapy and tyrosine kinase inhibitors. Sakaguchi M; Maebayashi T; Aizawa T; Ishibashi N; Saito T J Cancer Res Ther; 2020; 16(4):930-932. PubMed ID: 32930144 [TBL] [Abstract][Full Text] [Related]
2. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis. Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171 [TBL] [Abstract][Full Text] [Related]
3. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665 [TBL] [Abstract][Full Text] [Related]
4. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248 [TBL] [Abstract][Full Text] [Related]
5. Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Zhen J; Wen L; Lai M; Zhou Z; Shan C; Li S; Lin T; Wu J; Wang W; Xu S; Liu D; Lu M; Zhu D; Chen L; Cai L; Zhou C Radiat Oncol; 2020 Jul; 15(1):185. PubMed ID: 32736566 [TBL] [Abstract][Full Text] [Related]
6. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. Morris PG; Reiner AS; Szenberg OR; Clarke JL; Panageas KS; Perez HR; Kris MG; Chan TA; DeAngelis LM; Omuro AM J Thorac Oncol; 2012 Feb; 7(2):382-5. PubMed ID: 22089116 [TBL] [Abstract][Full Text] [Related]
7. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure. Yang H; Yang X; Zhang Y; Liu X; Deng Q; Zhao M; Xu X; He J Target Oncol; 2015 Mar; 10(1):135-40. PubMed ID: 24985049 [TBL] [Abstract][Full Text] [Related]
8. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711 [TBL] [Abstract][Full Text] [Related]
10. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer. Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536 [TBL] [Abstract][Full Text] [Related]
12. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer. Jia F; Cheng X; Zeng H; Miao J; Hou M J BUON; 2019; 24(2):578-584. PubMed ID: 31128009 [TBL] [Abstract][Full Text] [Related]
13. Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature. How J; Mann J; Laczniak AN; Baggstrom MQ Clin Lung Cancer; 2017 Jul; 18(4):354-363. PubMed ID: 28245967 [TBL] [Abstract][Full Text] [Related]
14. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations. Li YS; Jiang BY; Yang JJ; Tu HY; Zhou Q; Guo WB; Yan HH; Wu YL J Thorac Oncol; 2016 Nov; 11(11):1962-1969. PubMed ID: 27539328 [TBL] [Abstract][Full Text] [Related]
15. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027 [TBL] [Abstract][Full Text] [Related]
16. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. Zhou L; He J; Xiong W; Liu Y; Xiang J; Yu Q; Liang M; Zhou X; Ding Z; Huang M; Ren L; Zhu J; Li L; Hou M; Ding L; Tan F; Lu Y Lung Cancer; 2016 Jun; 96():93-100. PubMed ID: 27133757 [TBL] [Abstract][Full Text] [Related]
17. Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors. Ozdemir Y; Yildirim BA; Topkan E J Neurooncol; 2016 Sep; 129(2):329-35. PubMed ID: 27306442 [TBL] [Abstract][Full Text] [Related]
18. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review. Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275 [TBL] [Abstract][Full Text] [Related]